n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, August 31st, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Newgioco Group, Inc. (NWGI)

OTC Markets, TradingView, MarketWatch, and LAST10K reported on Newgioco Group, Inc. (NWGI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Newgioco Group, Inc. is a betting software technology company. It provides regulated leisure lottery and gaming products and services via licensed subsidiaries based in Europe. The Company, together with its wholly-owned subsidiaries, is a fully-licensed and integrated gaming software technology enterprise.

Newgioco Group has its corporate office in Toronto, Ontario, as well as an office in Rome, Italy. The Company’s shares trade on the OTC Markets’ OTCQB. Newgioco has acquired Multigioco Srl, which is a licensed gaming operator headquartered in Rome.

Newgioco Group plans to aggressively go after attractively priced, fragmented, and profitable gaming operators in Italy. Its aim is to become a top tier gaming operator over a five-year investment time horizon.

Newgioco Group provides its clients a complete set of leisure gaming products and services. These include sports betting, virtual sports, online casino, poker, bingo, lottery, interactive games and slots, and a unique betting platform (www.odissea.at) providing Business-to-Business (B2B) and Business-to-Consumer (B2C) bet processing. 

Newgioco Group conducts its business chiefly through retail neighborhood betting shops and an internet-based gambling and sports betting software platform under the registered brand Newgioco, by way of its licensed website www.newgioco.it located in Italy.

In July, Newgioco Group announced that it obtained certification on its betting software platform required by the Italian gaming authority, the Agency of Customs and Monopolies (ADM).  By attaining this globally recognized ADM Certification, Newgioco stated that it has demonstrated its dedication to the highest level of security standards and continuous improvement in betting software development, implementation, and oversight.

In early August, Newgioco Group announced the successful launch of its new Betting Platform Technology colloquially called "ELYS." The ELYS software platform went live on August 1, 2017. Therefore, sports betting operations are now processed in-house via ELYS, while skill games, lottery, casino, poker, and other entertainment products will continue through the Company’s strong relationship with Microgame SpA.

In addition, this month, Newgioco Group announced that it filed its 2017 Q2 results with the U.S. Securities and Exchange Commission (SEC). It reported Income Before Interest and Income Tax of $326,616. This represents a profit of $0.01 per share for Q2 of 2017. Non-GAAP Gaming Turnover saw a noticeable improvement, surpassing $102 million for the six months ended June 30, 2017, versus $54.9 million in the prior year.

GAAP Revenue was $7.97 million for the six months ended June 30, 2017, versus $3.27 million for the same period in 2016. This represents an increase of 143.5 percent. The Company’s Total Assets more than doubled from about $3.4 million to $7.25 million, and Cash reserves increased from $121,130 to $2.125 million.

Newgioco Group, Inc. (NWGI), closed Thursday's trading session at $0.978, up 22.25%, on 300 volume with 3 trades. The average volume for the last 60 days is 2,742 and the stock's 52-week low/high is $0.15/$1.30.

AXIM Biotechnologies, Inc. (AXIM)

TopPennyStockMovers, CFN Media Group, Promotion Stock Secrets, and SmallCapVoice reported previously on AXIM Biotechnologies, Inc. (AXIM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AXIM Biotechnologies, Inc. is a biotechnology company centering on the research, development, and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products. The Company discovers and brings to market unique solutions through research and development (R&D), strategic partnerships, and acquisitions through setting the green standard in the industrial hemp industry. Medical Marijuana, Inc. is a major investor in AXIM. OTCQB-listed, AXIM Biotechnologies is based in New York, New York.

AXIM’s concentration is on innovative proprietary delivery mechanisms for the introduction of cannabinoids and finding solutions for conditions for which there is currently no effective treatment. The Company is advancing its patented controlled-release cannabinoid gum in studies encompassing a number of indications. AXIM’s flagship CanChew Plus® contains 10mg of cannabidiol (CBD) obtained from industrial hemp plants.

AXIM Biotechnologies’ pipeline of Intellectual Property (IP) protected cannabinoid-based products additionally include MedChew Rx™. This THC/CBD cannabinoid controlled-release chewing gum is to address pain and muscle spasticity in multiple sclerosis (MS) patients. This pioneering invention is on path to be fully registered by the EMA and the Food and Drug Administration (FDA) by the end of 2017. It is the world’s first patented cannabinoid controlled-release chewing gum.

The Company’s products also include RENECANN™ - the world’s first cannabigerol (CBG)-based skincare product line. Furthermore, its products include ORAXIMAX™ - the world’s first CBG-based oral care product line; Suppocann™ - a suppository cannabinoid-release product for GI conditions including IBD, IBS and Crohn’s disease; and Ophthocann™ and Cannbleph™ - cannabinoid-based products for the lessening of intraocular pressure and for the relief of conjunctivitis.

AXIM® Biotechnologies earlier entered clinical trials at Wageningen University in the Netherlands for the treatment of irritable bowel syndrome (IBS) with AXIM's CanChew Plus® cannabidiol (CBD) gum. AXIM announced that it received approval from the Medical Ethical Committee (METC) at Wageningen University for the trial using controlled-release hemp oil CBD chewing gum with patients suffering from IBS.

AXIM Biotechnologies announced recently that it filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469. This is a patent of invention, which involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. In addition, the chewing gum may be used for the treatment of chronic pain.

AXIM Biotechnologies has entered into a Clinical Study Agreement (CSA) with the University of British Columbia to start a clinical trial with its CanChew Plus® cannabidiol (CBD) chewing gum product to treat drug-induced psychosis in adult patients. The University will work with Health Canada and its own ethics board to design the trial that will take place at the University of British Columbia, and will demonstrate the efficacy of AXIM Biotechnologies’ chewing gum product composed of 50mg CBD to treat drug-related psychosis.

AXIM’S IP portfolio now includes two fully issued patents – one patent permitting the use of CBD (cannabidiol) in controlled-release, functional chewing gum, and another patent for chewing gum containing natural and synthetic cannabinoids for the treatment of pain, and 15 patent applications in different stages of approval. AXIM now has registered 18 trademarks nationally and worldwide, with five more trademark applications pending all founded on products formulated and developed by AXIM Biotechnologies.

AXIM Biotechnologies, Inc. (AXIM), closed Thursday's trading session at $6.46, up 4.19%, on 14,199 volume with 115 trades. The average volume for the last 60 days is 28,716 and the stock's 52-week low/high is $0.21/$19.80.

Great Basin Scientific, Inc. (GBSN)

InvestorsUnderground, BUYINS.NET, The Weekly Options Trader, PennyPro, Investing Futures, Epic Stock Picks, Wolf of Penny Stocks, StreetInsider, Trader Power News, MarketClub Analysis, Jason Bond, Promotion Stock Secrets, Stock Beast, StockOodles, and Top Stock Picks reported earlier on Great Basin Scientific, Inc. (GBSN), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Great Basin Scientific, Inc. is a molecular diagnostics enterprise based in Salt Lake City, Utah. The Company’s mission is to quickly and accurately diagnose, reduce misdiagnoses, and significantly limit the spread of infectious disease. It commercializes ground-breaking chip-based technologies. Great Basin’s devotion is to the development of simple, yet strong, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. Great Basin Scientific lists on the OTCQB.

Great Basin Scientific has four commercially available assays: The Staph ID/R Blood Culture Panel, Shiga Toxin Direct Test, Group B Streptococcus (GBS) Test, and the Toxigenic Clostridium difficile (C. diff) Test. The Company also has five additional tests and panels in the development phase: Nasal S. aureus Pre-Screen, Candida Blood Infections Panel, Stool Bacterial Pathogens Panel, CT/NG Test, and Bordetella Direct Test.

The Company’s sample-to-result molecular diagnostics are fully automated with few hands-on steps. Depending on the target of interest, results are in two hours or less. Furthermore, sample-to-result molecular diagnostics feature on-demand testing. There is no upfront analyzer cost. Also, sample-to-result molecular diagnostics multiplexes up to 64 distinct targets in a single assay for more answers.

Great Basin Scientific’s diagnostic system empowers health providers with accurate and timely information. This information is for diagnosing infectious disease. This enables health providers to appropriately treat patients to improve outcomes and support antimicrobial stewardship. This results in shorter hospital stays and money saved.

Great Basin’s diagnostic system uses an integrated disposable cartridge containing all essential reagents. In addition, it uses an inexpensive bench-top analyzer. The analyzer executes the assay, interprets the results, and provides electronic output to the clinician. The user-friendly tests deliver more diagnostic data per sample.

Great Basin Scientific has received U.S. Food & Drug Administration (FDA) clearance for its Bordetella Direct Test, following a 510(k) submission on February 1, 2017. Great Basin received notification of clearance from the FDA on Friday, March 31, about 57 days from submission. The Bordetella Direct Test expands the Company’s menu of FDA cleared assays to five.

Great Basin Scientific is working to boost growth for the rest of 2017 and into 2018 via an expanded menu of diagnostic panels and tests. The Company’s new business pipeline surpasses $5.0 million. This represents an increase of 123 percent over Q4 of 2016.  New customer sites now comprise 34 percent of new business pipeline.

Recently, Great Basin Scientific announced it received FDA 510(k) clearance for its Stool Bacterial Pathogens Panel (SBPP). Greater than 40 hospitals and laboratories are now evaluating or are scheduled to evaluate SBPP, Great Basin’s second mid-plex panel.

Great Basin Scientific, Inc. (GBSN), closed Thursday's trading session at $0.07, up 7.69%, on 84,126 volume with 37 trades. The average volume for the last 60 days is 321,588 and the stock's 52-week low/high is $0.0555/$36,122.00.

GB Sciences, Inc. (GBLX)

Tip.us, Money Morning, SeriousTraders, Otcstockexchange, PennyStockInformer, Whisper from Wall Street, CFN Media Group, AllPennyStocks, Stockgoodies, SmallCapVoice, Cannabis Financial Network News, StocksToBuyNow, PennyStockLaboratory, Wall Street Resources, Wall St Report, Pumps and Dumps, and TradeThesePicks reported on GB Sciences, Inc. (GBLX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GB Sciences, Inc. is a biopharmaceutical Research and Development (R&D) company. Its emphasis is on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. GB Sciences is headquartered in Las Vegas, Nevada. The Company lists on the OTC Markets Group’s OTCQB.

GB Sciences’ R&D team is pursuing new formulations derived from specific strains of cannabis, creating patented formulations that will help patients. The Company provides clean, reliable raw materials for numerous cannabis products and research initiatives. It is creating novel formulations and seeking patents for treatments that will directly assist patients.

This past May, GB Sciences announced the initial harvest at its Cultivation Lab facility in Las Vegas. When fully operational, Cultivation Lab will contain 7,200 cannabis plants under 600 grow lights within its 28,000 ft.

The expectation is that Cultivation Lab will produce roughly $10 million in yearly revenue. The main directive of GB Sciences since the Company’s inception has been the creation of a quality controlled cannabis cultivation and extraction facility to provide the compounds for formulating medicines to treat a broad array of diseases.

GB Sciences has added its own medical-grade retail brand to its portfolio. This portfolio includes granted-medical and provisional-recreational use Nevada cultivation licenses and patent-pending medical formulations.

In July, GB Sciences announced it harvested its first crop and sold 63 pounds of premium flower while holding back 66.5 pounds for conversion to medical grade oil. GB Sciences (based on conservative estimates and production volumes) projects revenue of $2.8M through December 31, 2017. It will complete its full Fiscal Year (FY) projections (March 31, 2018) within the next few months.

GB Sciences signed a Consulting Services Agreement with Worldwide Clinical Trials, Inc. This Agreement is to evaluate its Intellectual Property (IP) portfolio and to assist with pre-IND planning for its proprietary cannabis-based formulations. These pre-IND consulting services will be performed by the Chief Medical and Scientific Officer (CMSO) of Worldwide, Mr. Michael F. Murphy, MD, PhD, as the representative of an extended Worldwide team.

Earlier this month, GB Sciences announced an agreement with the Los Coyotes Band of Cahuilla and Cupeno Indians (Los Coyotes) for establishing cannabis operations on the tribe's lands near Warner Springs, California. The nonbinding Joint Statement of Intent outlines plans to construct and operate facilities to grow, manufacture, as well as distribute commercial cannabis and cannabis products in California.

GB Sciences, Inc. (GBLX), closed Thursday's trading session at $0.255, up 7.37%, on 212,851 volume with 65 trades. The average volume for the last 60 days is 321,504 and the stock's 52-week low/high is $0.21/$0.65.

PharmaCyte Biotech, Inc. (PMCB)

SmallCapNetwork, Goldman Small Cap Research, InvestorPlace, Cannabis Financial Network News, BUYINS.NET, MyBestStockAlerts, Darth Trader, Fast Money Alerts, Penny Stock Beats, OTCJournal, Damn Good Penny Picks, Penny Picks, Wall Street Corner, Stock Market Media Group, Penny Stock General, PennyStockInformer, PennyStockLaboratory, Stock Shock and Awe, and The Stock Psycho reported previously on PharmaCyte Biotech, Inc. (PMCB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

PharmaCyte Biotech, Inc. centers on developing targeted treatments for cancer and diabetes applying its signature live cell encapsulation technology, Cell-in-a-Box®. This innovative and patented technology is being utilized as a platform upon which treatments for many types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. A clinical stage biotechnology company, PharmaCyte Biotech is based in Silver Spring, Maryland.

The Company is also working towards improving the quality of life of patients with advanced pancreatic cancer and on developing treatments for other types of solid cancerous tumors. PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the recognized anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible. This is to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer.

PharmaCyte is also developing treatments for cancer based upon chemical constituents of the Cannabis plant, called cannabinoids. It is studying ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.

The live-cell encapsulation technology that PharmaCyte Biotech employs is a way to enclose living cells in protective “cocoons” around the size of the head of a pin. The Company encapsulates living cells, not drugs.  Each capsule can enclose approximately 10,000 cells. This number can vary depending upon the size of the cells encapsulated. PharmaCyte Biotech is advancing its new treatment for pancreatic cancer into the clinic in the U.S, with study sites in Europe and Australia.

PharmaCyte Biotech announced this past April that its research partner, the University of Northern Colorado (UNC), has made considerable progress with PharmaCyte’s Cannabis Research Program. Notable is that a parental cell line identical to that being used in the Company’s Cell-in-a-Box® + ifosfamide pancreas cancer therapy is being used to develop a therapy for cancer using cannabinoids as the chemotherapy agent.

Recently, PharmaCyte Biotech announced the appointment of Dr. Michael M. Abecassis to the Company’s Board of Directors. Dr. Abecassis is a renowned transplantation surgeon at the Northwestern University Feinberg School of Medicine. Dr. Abecassis is the Director of the Comprehensive Transplant Center of the Feinberg School of Medicine. In addition, he is the Chief of Transplant Surgery in the Department of Surgery at Feinberg as well as a James Roscoe Miller Distinguished Professor of Medicine at Feinberg.

The Company also announced the appointment of Linda S. Sher, M.D. as its Chief Medical Officer. Dr. Sher is a Professor of Clinical Surgery and Director of Clinical Research in the Division of Hepatobiliary and Pancreatic Surgery and Abdominal Organ Transplantation at the University of Southern California’s (USC’s) Keck School of Medicine. Additionally, Dr. Sher is the Chief of the Division of Clinical Research for the Department of Surgery. She is also the Vice Chair of the USC Institutional Review Board.

PharmaCyte Biotech, Inc. (PMCB), closed Thursday's trading session at $0.06, down 2.44%, on 1,960,768 volume with 106 trades. The average volume for the last 60 days is 1,793,476 and the stock's 52-week low/high is $0.023/$0.1689.

graphic

The QualityStocks
Company Corner

graphic
graphic

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.3497, up 1.36%, on 88,495 volume with 50 trades. The stock’s average daily volume over the past 60 days is 81,738 and its 52-week low/high is $0.11/$0.699.

Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (CSE: LXX.CN) (CNSX: LXX) (the "Company" or "Lexaria") announces the world's first clinical study on human volunteers of cannabidiol (CBD) within Lexaria's high absorption TurboCBD™ product, to evaluate its effects on both cardiovascular health and cognitive function. Professor Philip Ainslie, PhD, Co-Director of the Centre for Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada, will be Principal Investigator of a team of co-investigators. UBC has consistently been ranked one of the top three universities in Canada, has over 62,000 students on two campuses, and is further considered one of the top research universities in the world. UBC has conducted several earlier studies in the cannabis sector, available for review at https://news.ubc.ca/tag/marijuana/.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria's TurboCBD

NetworkNewsWire Announces Publication Highlighting Companies Taking Innovative Strides in the Tobacco Industry

Lexaria Announces Exercised Warrants and Options

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0279, off by 3.79%, on 10,247,387 volume with 347 trades. The stock’s average daily volume over the past 60 days is 1,429,186, and its 52-week low/high is $0.0077/$0.04.

NetworkNewsWire, a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Global Payout, Inc. (OTC: GOHE), a client of NNW that provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The publication, titled, "Standout Fintech Companies Disrupt the Financial Services Landscape," discusses several public companies carving out their niche in the expanding financial services scene. To view the full publication, visit: https://www.networknewswire.com/standout-fintech-companies-disrupt-financial-services-landscape/

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

NetworkNewsWire Announces Publication Highlighting Innovative Public FINTECH Companies

NetworkNewsWire Releases Exclusive Interview with Global Payout, Inc. (GOHE)

Global Payout, Inc. Addresses Payment Challenges of Cannabis Industry with Incorporation of Bitcoin Technology

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.0766, up 2.13%, on 5,539,831 volume with 509 trades. The stock’s average daily volume over the past 60 days is 4,787,492, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PCAOB Registered CPA Firm Engaged to Initiate Audit on PotNetwork Holding, Inc.’s Recent Revenues

Mayweather vs. McGregor Event Brings Unprecedented Exposure to Diamond CBD and PotNetwork Holdings, “POTN”, as Sponsored Contenders Take the Spotlight

With Revenues over $1,459,137, PotNetwork Holding, Inc.’s Diamond CBD Continues to Exceed Projections, Bringing in the Highest Level of Monthly Sales to Date

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.0603, up 0.50%, on 28,180 volume with 5 trades. The stock’s average daily volume over the past 60 days is 26,563, and its 52-week low/high is $0.0308/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

Sully Project - E3 Target Drilling Underway

Kootenay Zinc Corp.: Sully Project Exploration Update

NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc Corp. (KTNNF)

Bollente Companies, Inc. (BOLC)

The QualityStocks Daily Newsletter would like to spotlight Bollente Companies, Inc. (BOLC). Today, Bollente Companies, Inc. closed trading at $0.834, up 17.46%, on 500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 1,547 and its 52-week low/high is $0.20/$1.21.

Bollente Companies, Inc. (BOLC) is in the early stages of developing a diverse portfolio of companies, targeting disruptive technologies that positively impact the environment and emerging economies. Their current focus is on high-efficiency electric tankless water heaters, manufactured and sold under "trutankless", a division of Bollente, including a line of economy tankless water heaters sold under the Vero name. Units are available for both residential and commercial application.

The primary Bollente advantage is their use of advanced technology, superior to previous tankless systems, together with a growing U.S. and global market. Traditional water heaters are one of the costliest appliances to operate. The two primary energy sources used in U.S. homes are electric and natural gas, with less than half of U.S. homes having natural gas available. In addition, there are no significant electric whole home tankless manufacturers.

The U.S. Department of Energy now requires tanks of 55 gallons or more to have efficiency levels requiring expensive heat pumps to achieve. Bollente's trutankless electric tankless water heater employs specialized sensors for constant water temperature, solid state electronics, and proprietary software, resulting in one of the most efficient heat exchangers ever produced. The technology includes smart grid and home automation capabilities, remote control and monitoring, and even smartphone alerts. It also allows adjustable custom power management settings, so that users can further enhance energy usage and performance. It is now estimated that tankless heaters used in every home would save over $8 billion annually in the U.S. alone.

By maintaining 99 percent efficiency, Bollente's trutankless heaters use less energy than tank heaters, while providing the convenience of always-hot water. The system only uses power when there is demand, producing water to exact temperature, within one degree, even with sudden changes to input. Wireless apps allow for remote settings, notifications, and monitoring, and models are compatible with existing home automation and energy management systems. The technology also reduces size, for easy location, and the system's self-flushing design provides up to 20+ years of maintenance free operation, significantly reducing upkeep and replacement costs. This becomes an additional environmental benefit since roughly 8 million used water heaters are dumped in landfills every year.

Bollente has also announced the formation of Bollente International, Inc., a wholly-owned subsidiary, for the international production and sale of trutankless systems. Taking advantage of growing interest in their technology, Bollente International is working with an international manufacturing firm for the production and distribution of trutankless systems throughout Europe, Asia, Australia and New Zealand, with the first step being the testing and certification necessary to meet the various international standards.

Bollente has made electric tankless water heating compelling to a major consumer market, both in and outside the U.S., offering economic as well as operational efficiency and convenience, attractive to builders as well as to end consumers. Disclaimer

Bollente Companies, Inc. Blog

Bollente Companies, Inc. News:

Bollente Companies Increases Production and Distribution Capabilities for trutankless® with Global Manufacturing Partnership

Bollente Companies Increases Presence in Trending Segment of Commercial Construction with Its Smart trutankless Product Line

Award-Winning Luxury Builder Cullum Homes Makes trutankless® the Exclusive Water Heating Solution in its Communities

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(IDDR) +223.64%

2.

OTCBB Journal
(PYDS) +44.79%

3.

Wolf of Penny Stocks
(ECEZ) +32.65%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251